Latest On Organogenesis Holdings Inc (ORGO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 23:19 EST | News | Organogenesis surges ~30% as Wound Care drives Q1 revenue; raises FY23 outlook | N/A |  |
| 2023-05-11 09:05 EST | News | Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 19:14 EST | News | Organogenesis Holdings reports Q1 results, raises FY 2023 revenue guidance | N/A | |
| 2023-05-10 05:58 EST | News | Organogenesis Holdings Q1 2023 Earnings Preview | N/A | |
| 2023-04-27 08:34 EST | News | Organogenesis President and CEO, also named to Chair of the Board | N/A | |
About Organogenesis Holdings Inc (ORGO):
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical tre read more...atment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
General
- Name Organogenesis Holdings Inc
- Symbol ORGO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 835
- Fiscal Year EndDecember
- IPO Date2017-01-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://organogenesis.com
Valuation
- Price/Sales (Trailing 12 Mt.) 5.96
- Price/Book (Most Recent Quarter) 34.56
- Enterprise Value Revenue 6.67
- Enterprise Value EBITDA 60.62
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate $0.11
- Next Year EPS Estimate $0.23
- Next Quarter EPS Estimate -$0.10
- Profit Margin 5%
- Operating Margin 8%
- Return on Assets 7%
- Return on Equity 18%
- Revenue 338.3 million
- Earnings Per Share -$0.58
- Revenue Per Share $3.14
- Gross Profit 250.98 million
- Quarterly Earnings Growth 43.1%
Highlights
- Market Capitalization 2.26 billion
- EBITDA 35.7 million
- PE Ratio -23.08
- Analyst Target Price $21
- Book Value Per Share $0.61
Share Statistics
- Shares Outstanding 127.99 million
- Shares Float 28.85 million
- % Held by Insiders 5551%
- % Held by Institutions 27.48%
- Shares Short 586932
- Shares Short Prior Month 1.04 million
- Short Ratio 0.82
- Short % of Float 1%
Technicals
- Beta 1.6
- 52 Week High $18.41
- 52 Week Low $2.69
- 50 Day Moving Average 14.12
- 200 Day Moving Average 7.5
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Organogenesis Holdings Inc (ORGO) Dividend Calendar:
Organogenesis Holdings Inc (ORGO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Organogenesis Holdings Inc (ORGO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Organogenesis Holdings Inc (ORGO) Chart:
Organogenesis Holdings Inc (ORGO) News:
Below you will find a list of latest news for Organogenesis Holdings Inc (ORGO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Organogenesis Holdings Inc (ORGO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ORGO Trades:
Organogenesis Holdings Inc (ORGO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-03 | 8-K (Current report) | |
| 2020-10-16 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-14 | 8-K (Current report) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-08-25 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-20 | 8-K (Current report) | |
| 2020-05-11 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-11 | 8-K (Current report) | |
| 2020-05-11 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-29 | 10-K/A (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-24 | 4 (Statement of changes in beneficial ownership of securities) | |
Organogenesis Holdings Inc (ORGO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Organogenesis Holdings Inc (ORGO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 5551%
Institutional Ownership: 2748%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-04-22 | WAYNE D MACKIE | Director | Buy | 18,564.00 | 118,564.00 | | ||
| 2020-04-22 | Patrick Bilbo | Chief Operating Officer | Buy | 34,035.00 | 155,835.00 | | ||
| 2020-04-22 | Joshua Alexander Tamaroff | Director | Buy | 18,564.00 | 18,564.00 | | ||
| 2020-04-22 | Arthur S Leibowitz | Director | Buy | 18,564.00 | 23,564.00 | | ||
| 2020-04-22 | Lori Freedman | VP and General Counsel | Buy | 26,918.00 | 26,918.00 | | ||
| 2020-04-22 | Timothy M. Cunningham | Chief Financial Officer | Buy | 27,847.00 | 27,847.00 | | ||
| 2020-04-22 | Brian Grow | Chief Commercial Officer | Buy | 32,488.00 | 35,767.00 | | ||
| 2020-04-22 | Gary S. Gillheeney | President and CEO | Buy | 88,181.00 | 486,081.00 | | ||
| 2020-04-22 | Antonio S. Montecalvo | VP Health Policy & Contracting | Buy | 24,134.00 | 63,066.00 | | ||
| 2020-04-14 | Brian Grow | Chief Commercial Officer | Buy | 1,150.00 | 1.70 | 1,955.00 | 3,279.00 | |
| 2020-03-16 | Avista Capital Managing Member IV, LLC | Director | Buy | 75,000.00 | 3.98 | 298,132.50 | 25,517,514.00 | |
| 2020-03-13 | Avista Capital Managing Member IV, LLC | Director | Buy | 135,000.00 | 4.31 | 581,283.00 | 25,442,514.00 | |
| 2020-03-12 | Avista Capital Managing Member IV, LLC | Director | Buy | 190,887.00 | 3.62 | 691,163.65 | 25,166,052.00 | |
| 2020-03-12 | Avista Capital Managing Member IV, LLC | Director | Buy | 141,462.00 | 4.17 | 590,377.51 | 25,307,514.00 | |
| 2020-02-05 | Gary S. Gillheeney | President and CEO | Buy | 397,900.00 | 1.70 | 676,430.00 | 397,900.00 | |
| 2020-01-21 | Antonio S. Montecalvo | VP Health Policy & Contracting | Buy | 30,450.00 | 1.70 | 51,765.00 | 38,932.00 | |
| 2019-11-26 | Avista Capital Managing Member IV, LLC | Director | Buy | 6,000,000.00 | 5.00 | 30,000,000.00 | 24,975,165.00 | |
| 2019-10-01 | Brian Grow | Chief Commercial Officer | Buy | 667.00 | 1.70 | 1,133.90 | 2,129.00 | |
| 2019-09-13 | WAYNE D MACKIE | Director | Buy | 1,032.00 | 6.07 | 6,267.54 | 100,000.00 | |
| 2019-09-13 | MICHAEL W KATZ | 10% Share Holder | Buy | 3,603.00 | 6.00 | 21,618.00 | 13,603.00 | |